This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Recombinant Vaccines Market

Market Insights on Recombinant Vaccines covering sales outlook, demand forecast & up-to-date key trends

Recombinant Vaccines Market By Product Type (Recombinant Vaccines, Attenuated Recombinant Vaccines, Vector Recombinant Vaccines), Distribution Channel (Hospitals, Private Clinics & Dispensaries, Retail Pharmacies & Others) & Region - Forecast 2018-2028

Improving Pipeline of New Pharmaceutical Products – Main Priority of Manufacturers

Various recombinant vaccines manufacturers have allotted a new capital framework to help shape their strategic priorities. Improving pipelines for new pharmaceutical products is the main priority for recombinant vaccines manufacturers and has the potential for a marked improvement in their performance. Manufacturers are investing behind their key recombinant vaccines, which is expected to drive growth the growth of the market in the coming years.

Increasing government initiatives for using recombinant vaccines in North, Europe, Latin America, and Asia pacific region is fueling the growth of the Recombinant Vaccines market. The growing demand for sustainable & optimized healthcare has increased the demand for Recombinant Vaccines. Moreover, ease of application of Recombinant Vaccines and the availability of Recombinant Vaccines through traditional supply chains are leading to increasing adoption rates of Recombinant Vaccines among distribution channel.

Customize this Report

Let us know your requirement to get
100% FREE customization

Lucrative Absolute Dollar Opportunities for Key Players in the Recombinant Vaccines Market

Recombinant vaccines haven’t infiltrated healthcare settings, especially in Middle East, Africa, and APEJ. Large number of patients are not aware about recombinant vaccines in not only the developing economies, but also a considerable portion of developed economies. Market players are yet to market recombinant vaccines efficiently in order to exploit their full market potential.

Awareness, advertisement, and proper marketing and are expected to help grab lucrative revenue opportunities over the forecast period. Although the adoption rate of recombinant vaccines is moderate in hospital settings globally, it poses a great market potential for manufacturers.

Recombinant Vaccines to Gain Popularity over the Forecast Period

Recombinant vaccines are projected to gain popularity as they provide great benefits for the patient, reduced side effect profiles, and reduced costs associated with therapeutic intervention as the hospital expenditure is reduced using recombinant vaccines.

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

80% Revenue Contribution by Leading Manufacturers in the Recombinant Vaccines Market

The recombinant vaccines market is mainly dominated by global manufactures. These manufacturers of recombinant vaccines are competing based on adoption of their respective recombinant vaccines. The increasing awareness about recombinant vaccines and a growing demand for optimized & sustainable healthcare has increased the revenue opportunity for the global manufacturers.

Companies like GlaxoSmithKline plc, and Merck & Co Inc, hold more than 80% revenue share in the global recombinant vaccines market. Launching novel products is one of the main focus of key market players. Also, companies operating in the recombinant vaccines market are collaborating with retailers and local distributors in order to increase the penetration of their respective recombinant vaccines.

Recombinant Vaccines Market Witnessing Considerable Growth in Asia Pacific

According to the discussions held with key opinion leaders in the recombinant vaccines market, a substantial growth has been witnessed in Asia Pacific market for recombinant vaccines market. Manufacturers in China & APEC are estimated to grow significantly in the recombinant vaccines market.

Become a MarketNgage Insider

An unified Market Research Subscription Platform, built for today’s disparate research needs.

Existing Alternate Product Categories Pose Challenges to the Growth of the Recombinant Vaccines Market

Recombinant vaccines face stiff competition from parallel product categories such as live attenuated vaccines. These vaccines offer broad spectrum immunity, and also reduce the number of dosages required. Attenuated vaccines are also known to be effective in stimulating both humoral as well as cellular immune responses. However, live attenuated vaccines in recombinant form could lead to disease transmission in immune-compromised hosts, which at times deter usage.

Recombinant Vaccines Market Download Report Brochure

Competitive Landscape

The company’s report titled “Recombinant Vaccines Market” provides detailed information about the growth parameters of the companies operating in the recombinant vaccines market. It includes detailed assessment of the competitive environment in the recombinant vaccines market.

The market study provides comprehensive data on each stakeholder in the recombinant vaccines market, including GlaxoSmithKline Biologicals, MERCK & CO., INC, Dynavax Technologies Corporation, Sanofi Pasteur, Bharat Biotech, Indian Immunologicals Limited, Serum Institute of India Pvt. Ltd., LG Chem, Sinovac Biotech Ltd, Pfizer, C.H. Boehringer Sohn AG & Co.KG. The report provides readers with all-encompassing data on each recombinant vaccine manufacturer’s revenue shares, winning strategies, and latest information on key strategies in the recombinant vaccines market.

Definition

Subunit recombinant vaccines are derived from killed vaccines. Their synthesis is non-toxic in nature. They contain highly immunogenic microbial antigens and are made with the help of recombinant DNA technology. Worth noting that the antigen component of subunit vaccines is covalently linked to a carrier, mostly a protein.

Attenuated recombinant vaccines are designed to specifically attenuate the microbe. Advantage of this type is mutant lesion in the microbe is specific, rather than randomly placed. These vaccines can be produced rapidly to meet sudden demands. Also it is easy to track the surveillance of these vaccines to revert back to virulence.

About the Report

The study on the recombinant vaccines market was recently published by the company, which provides comprehensive information about the most important market dynamics that prove instrumental in the growth of the recombinant vaccines market during 2018-2026. Companies in the recombinant vaccines market can find the most accurate quantitative and qualitative information about the growth parameters of the other recombinant vaccine manufacturers, which can help them develop data-driven business strategies in the coming future.

Additional Questions Answered

Readers can find detailed information about the important positive and negative factors affecting the recombinant vaccines market during the forecast period. Additionally, the report also contains valuable information that can provide recombinant vaccines manufacturers with answers to critical questions, such as

  • Which types of products account for the maximum demand for recombinant vaccines market? Why is it so?
  • Why are the sales of recombinant vaccines services and products highest in North America? What are the factors customers seek in Recombinant Vaccines?
  • Which factors are influencing the strategies of players in the recombinant vaccines market?
  • What are the current trends adopted by various companies?
  • What are the strategies being applied by the manufacturers in order to sustain themselves in the competitive market?

Research Methodology

The process of market research followed by the company commences with extensive secondary research of the recombinant vaccines market. We have obtained industry-validated, historic, and current data about the demand for recombinant vaccines across the globe. Comprehensive secondary research was followed by extensive and in-depth primary research, where detailed information about the recombinant vaccines market was obtained in terms of value (US$ Million).

Based on thorough secondary and primary research of the growth parameters of the recombinant vaccines market, we have come up with the most precise forecast on how the recombinant vaccines market will grow during the forecast period.

Segmentation

The report on the recombinant vaccines market provides salient information on market players. The recombinant vaccines market is segmented by region, product type, application, and distribution channel, to analyze segment-wise growth of the recombinant vaccines market. Based on regions, the recombinant vaccines market is segmented into seven regions – North America, Latin America, Western Europe, Eastern Europe, Asia Pacific Excluding Japan (APEJ), Japan, and the Middle East & Africa (MEA).

The recombinant vaccines market by product type is segmented intosubunit recombinant vaccines, attenuated recombinant vaccines, vector recombinant vaccines. By application, the recombinant vaccines market is segregated into human, and veterinary recombinant vaccines. By distribution channel, the recombinant vaccines market is segregated into hospitals, private clinics & dispensaries, retail pharmacies & others.

Frequently Asked Questions

Demand for recombinant vaccines is likely to grow at a CAGR of 8.75% through 2032.

Expanding the recombinant vaccines market size over to developing and some developed economies, due to unawareness.

Adoption of recombinant vaccines is likely to reach a valuation of US$ 42.08 Bn in 2022

GlaxoSmithKline Biologicals, MERCK & CO., INC., Dynavax Technologies Corporation, Sanofi Pasteur, Bharat Biotech, etc.

Table of Content

1. Executive Summary

    1.1. Market Overview

    1.2. Market Analysis

    1.3. FMI Analysis and Recommendations

    1.4. Wheel of Fortune

2. Market Introduction

    2.1. Market Taxonomy

    2.2. Market Definition

    2.3. Exclusion and Inclusion

    2.4. Target Market Analysis (US$ Mn), 2018

        2.4.1. Global Filtration Market

        2.4.2. Global Membrane Market

3. Market Dynamics

    3.1. Macro-Economic Factors

    3.2. Market Dynamics

        3.2.1. Drivers

        3.2.2. Restraints

        3.2.3. Trends

4. Key Inclusions

    4.1. Pricing Analysis

    4.2. Pipeline Analysis

5. North America Recombinant Vaccines Analysis 2013–2017 and Forecast 2018–2028

    5.1. Introduction

    5.2. Historical Market Value (US$ Mn) Analysis By Country, 2013-2017

        5.2.1. U.S.

        5.2.2. Canada

    5.3. Market Value (US$ Mn) Forecast By Country, 2018-2028

    5.4. Historical Market Value (US$ Mn) Analysis By Product Type, 2013-2017

        5.4.1. Subunit Recombinant Vaccines

        5.4.2. Attenuated Recombinant Vaccines

        5.4.3. Vector Recombinant Vaccines

    5.5. Market Value (US$ Mn) Forecast By Product Type, 2018-2028

    5.6. Historical Market Value(US$ Mn) Trend Analysis By Application, 2013-2017

        5.6.1. Human

        5.6.2. Veterinary

    5.7. Market Value(US$ Mn) Forecast By Application, 2018-2028

    5.8. Historical Market Value(US$ Mn) Trend Analysis By Distribution Channel, 2013-2017

        5.8.1. Hospitals

        5.8.2. Private Clinics & Dispensaries

        5.8.3. Retail Pharmacies

        5.8.4. Others

    5.9. Market Value(US$ Mn) Forecast By Distribution Channel, 2018-2028

    5.10. Market Attractiveness Analysis

        5.10.1. By Country

        5.10.2. By Product Type

        5.10.3. By Application

        5.10.4. By Distribution Channel

    5.11. Drivers and Restraints: Impact Analysis

    5.12. Key Market Participants – Intensity Mapping

6. Latin America Recombinant Vaccines Analysis 2013–2017 and Forecast 2018–2028

    6.1. Introduction

    6.2. Historical Market Value(US$ Mn) Analysis By Country, 2013-2017

        6.2.1. Brazil

        6.2.2. Mexico

        6.2.3. Argentina

        6.2.4. Rest of Latin America

    6.3. Market Value(US$ Mn) Forecast By Country, 2018-2028

    6.4. Historical Market Value (US$ Mn) Analysis By Product Type, 2013-2017

        6.4.1. Subunit Recombinant Vaccines

        6.4.2. Attenuated Recombinant Vaccines

        6.4.3. Vector Recombinant Vaccines

    6.5. Market Value (US$ Mn) Forecast By Product Type, 2018-2028

    6.6. Historical Market Value(US$ Mn) Trend Analysis By Application, 2013-2017

        6.6.1. Human

        6.6.2. Veterinary

    6.7. Market Value(US$ Mn) Forecast By Application, 2018-2028

    6.8. Historical Market Value(US$ Mn) Trend Analysis By Distribution Channel, 2013-2017

        6.8.1. Hospitals

        6.8.2. Private Clinics & Dispensaries

        6.8.3. Retail Pharmacies

        6.8.4. Others

    6.9. Market Value(US$ Mn) Forecast By Distribution Channel, 2018-2028

    6.10. Market Attractiveness Analysis

        6.10.1. By Country

        6.10.2. By Product Type

        6.10.3. By Application

        6.10.4. By Distribution Channel

    6.11. Drivers and Restraints: Impact Analysis

    6.12. Key Market Participants – Intensity Mapping

7. Western Europe Recombinant Vaccines Analysis 2013–2017 and Forecast 2018–2028

    7.1. Introduction

    7.2. Historical Market Value(US$ Mn) Analysis By Country, 2013-2017

        7.2.1. Germany

        7.2.2. U.K

        7.2.3. France

        7.2.4. Italy

        7.2.5. Spain

        7.2.6. Nordics

        7.2.7. Benelux

        7.2.8. Rest of Western Europe

    7.3. Market Value(US$ Mn) Forecast By Country, 2018-2028

    7.4. Historical Market Value (US$ Mn) Analysis By Product Type, 2013-2017

        7.4.1. Subunit Recombinant Vaccines

        7.4.2. Attenuated Recombinant Vaccines

        7.4.3. Vector Recombinant Vaccines

    7.5. Market Value (US$ Mn) Forecast By Product Type, 2018-2028

    7.6. Historical Market Value(US$ Mn) Trend Analysis By Application, 2013-2017

        7.6.1. Human

        7.6.2. Veterinary

    7.7. Market Value(US$ Mn) Forecast By Application, 2018-2028

    7.8. Historical Market Value(US$ Mn) Trend Analysis By Distribution Channel, 2013-2017

        7.8.1. Hospitals

        7.8.2. Private Clinics & Dispensaries

        7.8.3. Retail Pharmacies

        7.8.4. Others

    7.9. Market Value(US$ Mn) Forecast By Distribution Channel, 2018-2028

    7.10. Market Attractiveness Analysis

        7.10.1. By Country

        7.10.2. By Product Type

        7.10.3. By Application

        7.10.4. By Distribution Channel

    7.11. Drivers and Restraints: Impact Analysis

    7.12. Key Market Participants – Intensity Mapping

8. Eastern Europe Recombinant Vaccines Analysis 2013–2017 and Forecast 2018–2028

    8.1. Introduction

    8.2. Historical Market Value(US$ Mn) Analysis By Country, 2013-2017

        8.2.1. Russia

        8.2.2. Poland

        8.2.3. Rest of Eastern Europe

    8.3. Market Value(US$ Mn) Forecast By Country, 2018-2028

    8.4. Historical Market Value (US$ Mn) Analysis By Product Type, 2013-2017

        8.4.1. Subunit Recombinant Vaccines

        8.4.2. Attenuated Recombinant Vaccines

        8.4.3. Vector Recombinant Vaccines

    8.5. Market Value (US$ Mn) Forecast By Product Type, 2018-2028

    8.6. Historical Market Value(US$ Mn) Trend Analysis By Application, 2013-2017

        8.6.1. Human

        8.6.2. Veterinary

    8.7. Market Value(US$ Mn) Forecast By Application, 2018-2028

    8.8. Historical Market Value(US$ Mn) Trend Analysis By Distribution Channel, 2013-2017

        8.8.1. Hospitals

        8.8.2. Private Clinics & Dispensaries

        8.8.3. Retail Pharmacies

        8.8.4. Others

    8.9. Market Value(US$ Mn) Forecast By Distribution Channel, 2018-2028

    8.10. Market Attractiveness Analysis

        8.10.1. By Country

        8.10.2. By Product Type

        8.10.3. By Application

        8.10.4. By Distribution Channel

    8.11. Drivers and Restraints: Impact Analysis

    8.12. Key Market Participants – Intensity Mapping

9. Asia Pacific Excluding China & Japan Recombinant Vaccines Analysis 2013–2017 and Forecast 2018–2028

    9.1. Introduction

    9.2. Historical Market Value(US$ Mn) Analysis By Country, 2013-2017

        9.2.1. India

        9.2.2. China

        9.2.3. Australia and New Zealand

        9.2.4. ASEAN

        9.2.5. Rest of APECJ

    9.3. Market Value(US$ Mn) Forecast By Country, 2018-2028

    9.4. Historical Market Value (US$ Mn) Analysis By Product Type, 2013-2017

        9.4.1. Subunit Recombinant Vaccines

        9.4.2. Attenuated Recombinant Vaccines

        9.4.3. Vector Recombinant Vaccines

    9.5. Market Value (US$ Mn) Forecast By Product Type, 2018-2028

    9.6. Historical Market Value(US$ Mn) Trend Analysis By Application, 2013-2017

        9.6.1. Human

        9.6.2. Veterinary

    9.7. Market Value(US$ Mn) Forecast By Application, 2018-2028

    9.8. Historical Market Value(US$ Mn) Trend Analysis By Distribution Channel, 2013-2017

        9.8.1. Hospitals

        9.8.2. Private Clinics & Dispensaries

        9.8.3. Retail Pharmacies

        9.8.4. Others

    9.9. Market Value(US$ Mn) Forecast By Distribution Channel, 2018-2028

    9.10. Market Attractiveness Analysis

        9.10.1. By Country

        9.10.2. By Product Type

        9.10.3. By Application

        9.10.4. By Distribution Channel

    9.11. Drivers and Restraints: Impact Analysis

    9.12. Key Market Participants – Intensity Mapping

10. Japan Recombinant Vaccines Analysis 2013–2017 and Forecast 2018–2028

    10.1. Introduction

    10.2. Historical Market Value (US$ Mn) Analysis By Product Type, 2013-2017

        10.2.1. Subunit Recombinant Vaccines

        10.2.2. Attenuated Recombinant Vaccines

        10.2.3. Vector Recombinant Vaccines

    10.3. Market Value (US$ Mn) Forecast By Product Type, 2018-2028

    10.4. Historical Market Value(US$ Mn) Trend Analysis By Application, 2013-2017

        10.4.1. Human

        10.4.2. Veterinary

    10.5. Market Value(US$ Mn) Forecast By Application, 2018-2028

    10.6. Historical Market Value(US$ Mn) Trend Analysis By Distribution Channel, 2013-2017

        10.6.1. Hospitals

        10.6.2. Private Clinics & Dispensaries

        10.6.3. Retail Pharmacies

        10.6.4. Others

    10.7. Market Value(US$ Mn) Forecast By Distribution Channel, 2018-2028

    10.8. Market Attractiveness Analysis

        10.8.1. By Product Type

        10.8.2. By Application

        10.8.3. By Distribution Channel

    10.9. Drivers and Restraints: Impact Analysis

    10.10. Key Market Participants – Intensity Mapping

11. Middle East and Africa Recombinant Vaccines Analysis 2013–2017 and Forecast 2018–2028

    11.1. Introduction

    11.2. Historical Market Value(US$ Mn) Analysis By Country, 2013-2017

        11.2.1. GCC Countries

        11.2.2. South Africa

        11.2.3. Rest of Middle East and Africa

    11.3. Market Value(US$ Mn) Forecast By Country, 2018-2028

    11.4. Historical Market Value (US$ Mn) Analysis By Product Type, 2013-2017

        11.4.1. Subunit Recombinant Vaccines

        11.4.2. Attenuated Recombinant Vaccines

        11.4.3. Vector Recombinant Vaccines

    11.5. Market Value (US$ Mn) Forecast By Product Type, 2018-2028

    11.6. Historical Market Value(US$ Mn) Trend Analysis By Application, 2013-2017

        11.6.1. Human

        11.6.2. Veterinary

    11.7. Market Value(US$ Mn) Forecast By Application, 2018-2028

    11.8. Historical Market Value(US$ Mn) Trend Analysis By Distribution Channel, 2013-2017

        11.8.1. Human

        11.8.2. Veterinary

    11.9. Market Value(US$ Mn) Forecast By Distribution Channel, 2018-2028

    11.10. Market Attractiveness Analysis

        11.10.1. By Country

        11.10.2. By Product Type

        11.10.3. By Application

        11.10.4. By Distribution Channel

    11.11. Drivers and Restraints: Impact Analysis

    11.12. Key Market Participants – Intensity Mapping

12. Market Structure Analysis

    12.1. Market Structure by Tier

    12.2. Market Share Analysis (2017)

13. Competition Analysis

    13.1. Competition Dashboard

    13.2. Company Profiles

        13.2.1. GlaxoSmithKline Plc

            13.2.1.1. Overview of Division & Business Unit

            13.2.1.2. Analyst Commentary

            13.2.1.3. Key Developments

            13.2.1.4. Key Financials

        13.2.2. MERCK & CO., INC

        13.2.3. Dynavax Technologies Corporation

        13.2.4. Sanofi Pasteur

        13.2.5. Bharat Biotech

        13.2.6. Indian Immunologicals Limited

        13.2.7. Serum Institute of India Pvt. Ltd.

        13.2.8. LG Chem

        13.2.9. Sinovac Biotech Ltd

        13.2.10. Pfizer

        13.2.11. C.H. Boehringer Sohn AG & Co.KG

14. Global Recombinant Vaccines Analysis 2013–2017 and Forecast 2018–2028 By Region

    14.1. Introduction / Key Findings

    14.2. Historical Market Value(US$ Mn) Analysis By Region

        14.2.1. North America

        14.2.2. Latin America

        14.2.3. Western Europe

        14.2.4. Eastern Europe

        14.2.5. Asia Pacific Excluding Japan China

        14.2.6. Japan

        14.2.7. Middle East and Africa

    14.3. Market Value(US$ Mn) Forecast By Region

    14.4. Market Attractiveness Analysis By Region

15. Global Recombinant Vaccines Analysis 2013–2017 and Forecast 2018–2028, By Product Type

    15.1. Introduction/Key Finding

    15.2. Historical Market Value(US$ Mn) Analysis By Product Type, 2013-2017

        15.2.1. Subunit Recombinant Vaccines

        15.2.2. Attenuated Recombinant Vaccines

        15.2.3. Vector Recombinant Vaccines

    15.3. Market Value(US$ Mn) Forecast By Product Type, 2018-2028

    15.4. Market Attractiveness Analysis By Product Type

16. Global Recombinant Vaccines Analysis 2013–2017 and Forecast 2018–2028, By Application

    16.1. Introduction/Key Finding

    16.2. Historical Market Value(US$ Mn) Analysis By Application, 2013-2017

        16.2.1. Human

        16.2.2. Veterinary

    16.3. Market Value(US$ Mn) Forecast By Application, 2018-2028

    16.4. Market Attractiveness Analysis By Application

17. Global Recombinant Vaccines Analysis 2013–2017 and Forecast 2018–2028, By Distribution Channel

    17.1. Introduction/Key Finding

    17.2. Historical Market Value(US$ Mn) Analysis By Application, 2013-2017

        17.2.1. Hospitals

        17.2.2. Private Clinics & Dispensaries

        17.2.3. Retail Pharmacies

        17.2.4. Others

    17.3. Market Value(US$ Mn) Forecast By Application, 2018-2028

    17.4. Market Attractiveness Analysis By Application

18. Global Recombinant Vaccines Analysis 2013–2017 and Forecast 2018–2028

    18.1. Market Value Share Analysis By All Segment

    18.2. Y-o-Y Growth Analysis By All Segment

    18.3. Absolute $ Opportunity

19. Assumptions and Acronyms Used

20. Research Methodology

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

  1. North America Recombinant Vaccines Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Country

  2. North America Recombinant Vaccines Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Product Type

  3. North America Recombinant Vaccines Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Application Type

  4. North America Recombinant Vaccines Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Distribution Channel

  5. Latin America Recombinant Vaccines Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Country

  6. Latin America Recombinant Vaccines Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Product Type

  7. Latin America Recombinant Vaccines Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Application Type

  8. Latin America Recombinant Vaccines Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Distribution Channel

  9. Western Europe Recombinant Vaccines Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Country

  10. Western Europe Recombinant Vaccines Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Product Type

  11. Western Europe Recombinant Vaccines Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Application Type

  12. Western Europe Recombinant Vaccines Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Distribution Channel

  13. Eastern Europe Recombinant Vaccines Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Country

  14. Eastern Europe Recombinant Vaccines Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Product Type

  15. Eastern Europe Recombinant Vaccines Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Application Type

  16. Eastern Europe Recombinant Vaccines Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Distribution Channel

  17. APEJ Recombinant Vaccines Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Country

  18. APEJ Recombinant Vaccines Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Product Type

  19. APEJ Recombinant Vaccines Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Application Type

  20. APEJ Recombinant Vaccines Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Distribution Channel

  21. MEA Recombinant Vaccines Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Country

  22. MEA Recombinant Vaccines Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Product Type

  23. MEA Recombinant Vaccines Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Application Type

  24. MEA Recombinant Vaccines Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Distribution Channel

  25. Japan Recombinant Vaccines Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Product Type

  26. Japan Recombinant Vaccines Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Application Type

  27. Japan Recombinant Vaccines Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Distribution Channel

  28. Global Recombinant Vaccines Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Country

  29. Global Recombinant Vaccines Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Product Type

  30. Global Recombinant Vaccines Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Application Type

  31. Global Recombinant Vaccines Market Size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028, By Distribution Channel

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

List of Charts

  1. North America Recombinant Vaccines Market, Snapshot

  2. North America Recombinant Vaccines Market Value Share, by Country (2017)

  3. North America Recombinant Vaccines Market Value Share, by Product Type (2017)

  4. North America Recombinant Vaccines Market Value Share, by Application Type (2017)

  5. North America Recombinant Vaccines Market Value Share, by Distribution Channel (2017)

  6. North America Recombinant Vaccines Market Size (US$ Mn) Analysis, 2013–2017

  7. North America Recombinant Vaccines Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018–2028

  8. North America Recombinant Vaccines Market Attractiveness Analysis, By Country

  9. North America Recombinant Vaccines Market Attractiveness Analysis, By Product Type

  10. North America Recombinant Vaccines Market Attractiveness Analysis, By Application

  11. North America Recombinant Vaccines Market Attractiveness Analysis, By Distribution Channel

  12. Latin America Recombinant Vaccines Market, Snapshot

  13. Latin America Recombinant Vaccines Market Value Share, by Country (2017)

  14. Latin America Recombinant Vaccines Market Value Share, by Product Type (2017)

  15. Latin America Recombinant Vaccines Market Value Share, by Application Type (2017)

  16. Latin America Recombinant Vaccines Market Value Share, by Distribution Channel (2017)

  17. Latin America Recombinant Vaccines Market Size (US$ Mn) Analysis, 2013–2017

  18. Latin America Recombinant Vaccines Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018–2028

  19. Latin America Recombinant Vaccines Market Attractiveness Analysis, By Country

  20. Latin America Recombinant Vaccines Market Attractiveness Analysis, By Product Type

  21. Latin America Recombinant Vaccines Market Attractiveness Analysis, By Application

  22. Latin America Recombinant Vaccines Market Attractiveness Analysis, By Distribution Channel

  23. Western Europe Recombinant Vaccines Market, Snapshot

  24. Western Europe Recombinant Vaccines Market Value Share, by Country (2017)

  25. Western Europe Recombinant Vaccines Market Value Share, by Product Type (2017)

  26. Western Europe Recombinant Vaccines Market Value Share, by Application Type (2017)

  27. Western Europe Recombinant Vaccines Market Value Share, by Distribution Channel (2017)

  28. Western Europe Recombinant Vaccines Market Size (US$ Mn) Analysis, 2013–2017

  29. Western Europe Recombinant Vaccines Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018–2028

  30. Western Europe Recombinant Vaccines Market Attractiveness Analysis, By Country

  31. Western Europe Recombinant Vaccines Market Attractiveness Analysis, By Product Type

  32. Western Europe Recombinant Vaccines Market Attractiveness Analysis, By Application

  33. Western Europe Recombinant Vaccines Market Attractiveness Analysis, By Distribution Channel

  34. Eastern Europe Recombinant Vaccines Market, Snapshot

  35. Eastern Europe Recombinant Vaccines Market Value Share, by Country (2017)

  36. Eastern Europe Recombinant Vaccines Market Value Share, by Product Type (2017)

  37. Eastern Europe Recombinant Vaccines Market Value Share, by Application Type (2017)

  38. Eastern Europe Recombinant Vaccines Market Value Share, by Distribution Channel (2017)

  39. Eastern Europe Recombinant Vaccines Market Size (US$ Mn) Analysis, 2013–2017

  40. Eastern Europe Recombinant Vaccines Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018–2028

  41. Eastern Europe Recombinant Vaccines Market Attractiveness Analysis, By Country

  42. Eastern Europe Recombinant Vaccines Market Attractiveness Analysis, By Product Type

  43. Eastern Europe Recombinant Vaccines Market Attractiveness Analysis, By Application

  44. Eastern Europe Recombinant Vaccines Market Attractiveness Analysis, By Distribution Channel

  45. APEJ Recombinant Vaccines Market, Snapshot

  46. APEJ Recombinant Vaccines Market Value Share, by Country (2017)

  47. APEJ Recombinant Vaccines Market Value Share, by Product Type (2017)

  48. APEJ Recombinant Vaccines Market Value Share, by Application Type (2017)

  49. APEJ Recombinant Vaccines Market Value Share, by Distribution Channel (2017)

  50. APEJ Recombinant Vaccines Market Size (US$ Mn) Analysis, 2013–2017

  51. APEJ Recombinant Vaccines Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018–2028

  52. APEJ Recombinant Vaccines Market Attractiveness Analysis, By Country

  53. APEJ Recombinant Vaccines Market Attractiveness Analysis, By Product Type

  54. APEJ Recombinant Vaccines Market Attractiveness Analysis, By Application

  55. APEJ Recombinant Vaccines Market Attractiveness Analysis, By Distribution Channel

  56. MEA Recombinant Vaccines Market, Snapshot

  57. MEA Recombinant Vaccines Market Value Share, by Country (2017)

  58. MEA Recombinant Vaccines Market Value Share, by Product Type (2017)

  59. MEA Recombinant Vaccines Market Value Share, by Application Type (2017)

  60. MEA Recombinant Vaccines Market Value Share, by Distribution Channel (2017)

  61. MEA Recombinant Vaccines Market Size (US$ Mn) Analysis, 2013–2017

  62. MEA Recombinant Vaccines Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018–2028

  63. MEA Recombinant Vaccines Market Attractiveness Analysis, By Country

  64. MEA Recombinant Vaccines Market Attractiveness Analysis, By Product Type

  65. MEA Recombinant Vaccines Market Attractiveness Analysis, By Application

  66. MEA Recombinant Vaccines Market Attractiveness Analysis, By Distribution Channel

  67. Japan Recombinant Vaccines Market, Snapshot

  68. Japan Recombinant Vaccines Market Value Share, by Product Type (2017)

  69. Japan Recombinant Vaccines Market Value Share, by Application (2017)

  70. Japan Recombinant Vaccines Market Value Share, by Distribution Channel (2017)

  71. Japan Recombinant Vaccines Market Size (US$ Mn) Analysis, 2013–2017

  72. Japan Recombinant Vaccines Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018–2028

  73. Japan Recombinant Vaccines Market Attractiveness Analysis, By Product Type

  74. Japan Recombinant Vaccines Market Attractiveness Analysis, By Application

  75. Japan Recombinant Vaccines Market Attractiveness Analysis, By Distribution Channel

  76. Global Recombinant Vaccines Market Size (US$ Mn) Analysis, 2013–2017

  77. Global Recombinant Vaccines Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2018–2028

  78. Global Recombinant Vaccines Market Attractiveness Analysis, By Region

  79. Global Recombinant Vaccines Market Value Share Analysis, By Region, 2017 & 2028

  80. Global Recombinant Vaccines Market Attractiveness Analysis, By Product Type

  81. Global Recombinant Vaccines Market Value Share Analysis, By Product Type, 2017 & 2028

  82. Global Recombinant Vaccines Market Attractiveness Analysis, By Application Type

  83. Global Recombinant Vaccines Market Value Share Analysis, By Application Type, 2017 & 2028

  84. Global Recombinant Vaccines Market Attractiveness Analysis, By Distribution Channel

  85. Global Recombinant Vaccines Market Value Share Analysis, By Distribution Channel, 2017 & 2028

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports
Google translate

Recombinant Vaccines Market